Abstract
INTRODUCTION In the past 10 years, autologous stem cell transplantation (ASCT) has emerged as a major new form of treatment for a variety of malignant diseases. Indeed, the overall number of autologous transplants registered with the Autologous Blood and Marrow Transplant Registry (ABMTR) in a 5-year period ending in 1994 was 16,561 (1). This exponential growth can be attributed to a variety of new developments, which shall be reviewed below.